Cite
HARVARD Citation
Altarac, D. et al. (n.d.). 732. Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections. Open forum infectious diseases. p. . [Online].